AmplifyBio to Drive Quality Excellence with Veeva Vault Quality Suite

Rhea-AI Summary

On May 3, 2022, Veeva Systems (NYSE: VEEV) announced that AmplifyBio will utilize its Veeva Vault Quality Suite to enhance quality management in preclinical drug testing. This collaboration aims to streamline processes and ensure compliance with stringent GLP requirements, facilitating better data generation for FDA submissions. AmplifyBio, a CRO specializing in toxicology and safety pharmacology, will leverage various Veeva products to manage quality consistently across its operations. The initiative underscores Veeva's commitment to supporting advancements in the life sciences sector.

Positive

• AmplifyBio will utilize Veeva Vault Quality Suite to streamline preclinical testing processes.
• Collaboration enhances AmplifyBio's data reliability for FDA submissions.
• Veeva's technology supports compliance with GLP requirements, ensuring quality excellence.

Negative

• None.

Fast-growing CRO will bring together quality processes, content, and training to streamline quality management and accelerate preclinical validation for cutting-edge medicines

PLEASANTON, Calif., May 3, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that AmplifyBio is building a foundation for advanced quality, study execution, and reporting with Veeva Vault Quality Suite. Using a modern quality system with built-in industry best practices, the company will streamline and automate processes to increase the efficiency of its preclinical drug testing.

"At AmplifyBio, we generate and report critical data through short and long duration studies that go into FDA submissions for many of our clients at a key stage in developing medicines," said Jerry Hacker, executive vice president and chief commercial officer at AmplifyBio. "With our state-of-the-art facility and Veeva Vault Quality Suite, we will deliver data our clients can rely on while keeping up with the most rigorous GLP requirements."

AmplifyBio is a contract research organization (CRO) focused on toxicology, safety pharmacology, and efficacy testing to accelerate innovation across pharmaceutical modalities. The company will use Veeva Vault QMS to execute core quality processes, Veeva Vault QualityDocs to manage and share SOPs and other GLP documents, and Veeva Vault Training to ensure role-based qualifications. By managing end-to-end quality in a single system, AmplifyBio will be able to ensure quality excellence across its departments and suppliers.

"As a trusted partner, we're proud to support AmplifyBio's vision of advancing medical breakthroughs and cures for disease," said Ashley Wentworth, senior director, Veeva Vault Quality strategy. "With Veeva Vault Quality Suite, AmplifyBio will have a technology foundation that can scale and keep up with evolving customer and market needs."

Vault Quality Suite includes Vault QMS, Veeva Vault Product Surveillance, Vault QualityDocs, Veeva Vault Validation Management, Veeva Vault Station Manager, Vault Training, Veeva LearnGxP, and Veeva Vault LIMS to automate and harmonize quality processes globally. Vault Quality Suite enables companies to easily manage quality in one unified solution and delivers the power and scalability needed across the life sciences value chain.

Additional Information

For more on Veeva Vault Quality Suite, visit: veeva.com/VaultQuality Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veevasystems on Twitter: twitter.com/veevasystems 

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the period ended January 31, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amplifybio-to-drive-quality-excellence-with-veeva-vault-quality-suite-301538213.html

SOURCE Veeva Systems

FAQ

How will Veeva's technology impact AmplifyBio's operations?

Veeva's technology will streamline and automate quality management processes at AmplifyBio, enhancing efficiency in preclinical drug testing.

What is the significance of the Veeva Vault Quality Suite for VEEV?

The Veeva Vault Quality Suite is crucial for Veeva Systems as it strengthens their position in providing advanced quality management solutions in the life sciences industry.

When was the partnership between Veeva and AmplifyBio announced?

The partnership was announced on May 3, 2022.

What areas does AmplifyBio focus on in medical research?

AmplifyBio specializes in toxicology, safety pharmacology, and efficacy testing to accelerate pharmaceutical innovation.